Artiva Biotherapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | $0 | $251.0K | $33.5M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $69.5M | $50.3M | $50.3M |
| SG&A Expense | — | $20.3M | $17.2M | $13.9M |
| Operating Income | — | $-89.8M | $-67.3M | $-30.7M |
| Operating Margin | — | — | -26,805.6% | -91.6% |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | $-65.4M | $-28.6M |
| Income Tax Expense | — | $0 | $0 | $72.0K |
| Net Income | — | $-83.9M | $-65.4M | $-28.7M |
| Net Margin | — | — | -26,045.0% | -85.8% |
| EPS (Basic) | — | $-3.43 | $-2.91 | $-1.28 |
| EPS (Diluted) | — | $-3.43 | $-2.91 | $-1.28 |
| Shares Outstanding (Basic) | 24.7M | 24.4M | 22.5M | 22.5M |
| Shares Outstanding (Diluted) | 24.7M | 24.4M | 22.5M | 22.5M |
| Dividends Per Share | — | — | — | — |